-

Hongke Peng – Blood Cells & Blood Cancer division

23/02/2024 3:00 pm - 23/02/2024 4:00 pm
Location
Davis Auditorium

WEHI PhD Completion Seminar hosted by Professor David Huang

Hongke Peng

PhD Student – Huang Laboratory, Blood Cells & Blood Cancer division – Cancer Research & Treatments Theme, WEHI

 

Using single-cell multi-omics to discover approaches for enhancing venetoclax therapy

 

Davis Auditorium

Join via SLIDO enter code #WEHIphdcompletion

Including Q&A session

Followed by refreshments in Tapestry Lounge

 

Single-cell RNA sequencing (scRNA-seq) techniques offer a novel approach to exploring the heterogeneity of cancers. These techniques have undergone rapid development over the past decade. One such innovation is cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq). This approach can connect transcriptomics and surface proteomics at the single-cell level. We applied CITE-seq to chronic lymphocytic leukaemia (CLL) patient samples to answer the clinical question of how the microenvironment plays a role in venetoclax resistance. CLL is the most common type of adult leukaemia in western countries. The BCL2-inhibitor venetoclax shows remarkable clinical efficiency in treating patients with CLL. However, the disease relapses in most patients after years of venetoclax monotherapy. Among patients with the relapsed disease, multiple sub-clones harbouring distinct mechanisms of resistance often co-exist. Therefore, understanding the heterogeneity of CLL is critical to addressing the challenge of drug resistance and disease relapse.

 

In this seminar, I will present my work on applying CITE-seq to patient lymph node samples to identify the potential mechanisms of venetoclax resistance induced by the microenvironment. Specifically, I observed that T-cell exhaustion was associated with the emergence of venetoclax resistance in CLL patients.  Therefore, I investigated the impact of venetoclax on the immune systems of patients with solid tumours who received the treatment to explore the rationality of combining venetoclax with immunotherapies. In addition, I will also discuss my work in developing new methods for isoform detection and mutation calling at single-cell resolution.

 

All welcome!

Support us

Together we can create a brighter future

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Sign up to our quarterly newsletter Illuminate

Find out about recent discoveries, community supporters and more.

Illuminate Summer 2023
View the current issue